Compare Baker Hughes Co (BKR) vs Charles River Laboratories Intl. Inc (CRL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Baker Hughes Co vs Charles River Laboratories Intl. Inc — how do they compare? Baker Hughes Co trades at $65.06 (market cap $64.34B), while Charles River Laboratories Intl. Inc trades at $286.05 (market cap $13.46B). The key difference: Baker Hughes Co is far larger — about 4.8× Charles River Laboratories Intl. Inc's market cap, and Baker Hughes Co pays a 1.42% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals.
| BKR | CRL | |
|---|---|---|
Market Cap | $64.34B | $13.46B |
Sector | Energy | Health |
52-Week High | $69.67 | $282.00 |
52-Week Low | $42.51 | $145.57 |
Enterprise Value | $64.86B | $16.30B |
Dividend Yield | 1.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Baker Hughes (BKR) trades at $64.94, up 1.35% on the day, with a bullish technical signal and strong earnings beats in recent quarters. The company demonstrates robust fundamentals with a P/E of 20.84, ROE of 16.47%, and positive cash flow trends. Recent news highlights major contract wins in subsea systems and LNG technology, signaling strong demand for its energy infrastructure solutions.
The outlook for BKR is positive, supported by analyst consensus and operational strength, though risks include integration challenges from acquisitions and potential volatility in oil & gas spending. The stock presents an opportunity for growth investors seeking exposure to energy technology, with a consensus price target of $73.25 implying potential upside.
Charles River Laboratories (CRL) trades at $277.00, up 3.56% on the day and near its 52-week high of $277.07, reflecting strong bullish momentum. The stock exhibits positive technical signals with moving averages indicating an uptrend, though oscillators suggest overbought conditions. Fundamentally, the company reported Q2 2026 EPS of $3.02, beating estimates, and raised full-year guidance, yet faces profitability challenges with a negative net income margin of -5.96% and elevated valuation ratios like a P/E of 684.85. Recent news highlights improved biotech demand and institutional buying interest.
The outlook for CRL is cautiously optimistic, driven by earnings beats and raised guidance, but high valuation and weak profitability pose risks. Investment opportunity lies in sustained demand for drug development services, while risks include margin pressure, debt levels, and sensitivity to biotech funding cycles. The stock's proximity to all-time highs warrants monitoring for pullbacks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Baker Hughes Co
Baker Hughes is a global leader in oilfield services and oilfield equipment, with particularly strong presences in the artificial lift, specialty chemicals, and completions markets. The other half of its business focuses on industrial power generation, process solutions, and industrial asset management, with high exposure to the liquid natural gas market specifically, as well as broader industrials end markets.
Read more on BKR →About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →
